Phase 2 Study of Single-Agent IV Vinflunine as Third-Line Treatment of Metastatic Breast Cancer After Failure of Anthracycline-/Taxane-Based Chemotherapy

Objective:A multicenter, open-label, phase 2 study evaluated the efficacy and safety of intravenous vinflunine as third-line treatment in patients with progressing metastatic breast cancer (MBC) after failure of anthracycline- and taxane-based chemotherapy.Patients and Methods:Fifty-six patients wit